Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia

Pediatr Blood Cancer. 2024 Jun;71(6):e30974. doi: 10.1002/pbc.30974. Epub 2024 Mar 24.

Authors

Ramya Ramakrishnan¹, Faryal Munir¹, Andres Ernesto Quesada², Johann Hitzler³, Branko Cuglievan¹

Affiliations

¹ Department of Pediatrics, Pediatric Hematology Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Division of Hematology Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

PMID: 38523255
DOI: 10.1002/pbc.30974

No abstract available

Publication types

Letter

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Azacitidine / administration & dosage
Azacitidine / therapeutic use
Child, Preschool
Cytarabine* / administration & dosage
Cytarabine* / therapeutic use
Decitabine / administration & dosage
Decitabine / pharmacology
Decitabine / therapeutic use
Down Syndrome* / complications
Down Syndrome* / drug therapy
Female
Humans
Infant
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / pathology
Male

Substances

Cytarabine
Decitabine
Azacitidine
Antimetabolites, Antineoplastic